Alcoi

Researchers are evaluating camizestrant against standard endocrine therapy for patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. These patients must have completed locoregional therapy and at least 2 to 5 years of standard adjuvant endocrine therapy. The study is a Phase III open-label trial focused on improving outcomes for these patients over a long-term period. Participants are randomly assigned to receive either camizestrant orally or continue with the standard endocrine therapy chosen by their investigator, which may include aromatase inhibitors exemestane, letrozole, anastrozole or tamoxifen. Treatment in each group lasts for 60 months. The study allows prior use of CDK46 inhibitors and includes a follow-up period extending up to 10 years from the last patient randomization. During the study, participants will undergo regular assessments to monitor invasive breast cancer-free survival and other outcomes such as invasive disease-free survival, distant relapse-free survival, overall survival, and safety. Researchers will also evaluate symptoms like joint pain, hot flushes, and vaginal dryness using specific scales, along with quality of life measures and pharmacokinetics. Safety monitoring continues up to 28 days after the last dose, and participants remain under observation for up to 10 years total.

Researchers are conducting an observational, multicenter study to collect and analyze medical information from patients diagnosed with advanced metastatic or unresectable melanoma. The study focuses on understanding the characteristics of these patients at their first diagnosis, either as initial metastatic or unresectable disease or as the first metastatic relapse after previous treatment for localized melanoma. This research aims to provide important insights into melanoma progression and treatment patterns in Spain. The study observes patients receiving usual clinical care without assigning any specific treatment or intervention. Treatment decisions are made independently by the patients healthcare providers as part of routine medical practice. Patients included have been diagnosed with stage III, metastatic, or unresectable melanoma since January 8, 2018, and their medical records will be reviewed to gather relevant data. Participants involvement primarily involves the collection of information from their medical records, with no additional diagnostic or follow-up procedures beyond standard care. Researchers will review baseline sample characteristics to understand patient profiles at diagnosis. The study does not involve any direct intervention or changes to treatment and focuses on long-term data collection to support melanoma research and patient care improvements.

Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.

Researchers are conducting an observational, epidemiological study to understand thrombosis in patients diagnosed with cancer. This study focuses on patients who experience venous or arterial thromboembolic events, either symptomatic or incidental, occurring within a month before cancer diagnosis or any time afterward. The study collects detailed information about the characteristics and timing of these events in relation to cancer diagnosis to better understand this condition. The study does not involve any interventions or treatments, as it is non-interventional and observational. Data is gathered from multiple centers, tracking details such as the location and vessel of origin of the thromboembolic event, tumor characteristics, and treatment administered for cancer at baseline. Patients are followed up for 12 months to assess their situation and outcomes related to thrombosis and cancer. Participants are involved through data collection at baseline and follow-up visits. Researchers assess imaging-confirmed thromboembolic events using techniques like Doppler echocardiography and CT angiography. The study measures various outcomes including event diagnosis, tumor stage, timing between cancer diagnosis and thrombosis, and patient status at one year. This registry provides valuable information about cancer-associated thrombosis over time.

This research aims to collect detailed information about patients with lung cancer and other thoracic tumors to better understand the disease and treatment outcomes. It focuses on individualizing treatment based on markers that predict response to chemotherapy and molecular inhibitors. The study addresses challenges such as poor prognosis, variability in diagnosis and treatment, and the need for improved early detection and prevention strategies across Europe and Spain. The study is observational and multicenter, gathering data both retrospectively and prospectively from patients diagnosed and treated by medical professionals including thoracic surgeons and oncologists. It includes multiple groups of patients based on the type of thoracic tumor, such as non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic cancer, and carcinoid cancer. There are no experimental treatments instead, it involves comprehensive data collection on patient characteristics and treatments. Participants provide information from their medical history and treatment records over up to 10 years. Researchers study epidemiological and therapeutic factors related to thoracic tumors by reviewing clinical data. The main outcome is to describe characteristics of these tumors in Spanish patients. The study involves no interventions or medications, focusing on observation and data analysis to inform future care and research.